GNPX vs GRCE

Genprex, Inc. vs Grace Therapeutics, Inc. — Valuation Comparison 2026

GNPX

Biotechnology
Genprex, Inc.
Quality
3.9
out of 10
Value Trap
24
SAFE
Price
$0.79
Last close
Models
7/13
Active
VS

GRCE

Biotechnology
Grace Therapeutics, Inc.
Quality
4.6
out of 10
Value Trap
52
WARN
Price
$2.43
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType GNPX Fair ValueGNPX Upside GRCE Fair ValueGRCE Upside
Bayesian DCF Intrinsic $1.15 +44.2% $1.31 -46.0%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.06 -93.8% $4.05 +66.7%
Dynamic NAV Asset-Based $2.93 +269.2% $3.38 +39.2%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for GNPX vs GRCE — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

GNPX vs GRCE — Which Stock Is More Undervalued?

GRCE scores higher with a 4.6/10 quality rating vs GNPX's 3.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Genprex, Inc. (GNPX) and Grace Therapeutics, Inc. (GRCE) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

GNPX currently trades at $0.79 with a QOC of 3.9/10, while GRCE trades at $2.43 with a QOC of 4.6/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).